{"uid":"cap_n8CanZ7ZFBHWYq1JM-SKL","slug":"jeetscreener-io-3bd74765","name":"JeetScreener Market News Headlines by Ticker","description":"Latest market news headlines with ticker tags - curated for active traders","url":"https://jeetscreener.io/api/signals/news/market","method":"GET","headers":{},"bodySchema":{"type":"object","required":["ticker"],"properties":{"ticker":{"type":"string"}}},"responseSchema":{"type":"array","items":{"type":"object","required":["id","summary","tickers","headline","publishedAt"],"properties":{"id":{"type":"string"},"summary":{"type":"string"},"tickers":{"type":"array","items":{"type":"string"}},"headline":{"type":"string"},"publishedAt":{"type":"number"}}}},"example":{"request":{"ticker":"BTC"},"response":[{"id":"n_51898553","summary":" Up to 4,494,279 Shares of Common StockThis prospectus relates to the resale from time to time of up to 4,494,279 shares of common stock, par value $0.0001 per share (the "Shares"), of Evommune, Inc. by the selling","tickers":["EVMN"],"headline":"Evommune Files Prospectus For Resale Of Up To 4,494,279 Shares Of Common Stock By Selling Stockholders","publishedAt":1776456661},{"id":"n_51898507","summary":"Vera Bradley, Inc. (NASDAQ: VRA) (the "Company") announced today that the Company's Board of Directors (the "Board") unanimously approved an amendment (the "Amendment") to the Company's existing shareholder rights planVera Bradley, Inc.","tickers":["VRA"],"headline":"Vera Bradley Board Terminates Existing Shareholder Rights Plan, Effective April 17","publishedAt":1776456570},{"id":"n_51898432","summary":"- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple","tickers":["TOVX"],"headline":"Theriva Biologics' VCN-01 Shows Immune-Mediated Activity And Improved Outcomes Across Subgroups In Phase 2b Pancreatic Cancer Trial At AACR 2026","publishedAt":1776456508},{"id":"n_51898432","summary":"- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple","tickers":["TOVX"],"headline":"Theriva Biologics' VCN-01 Shows Immune-Mediated Activity And Improved Outcomes Across Subgroups In Phase 2b Pancreatic Cancer Trial At AACR 2026","publishedAt":1776456508},{"id":"n_51898413","summary":"https://www.sec.gov/Archives/edgar/data/1866030/000149315226017831/formf-3.htm","tickers":["AZ"],"headline":"A2Z Cust2Mate Files Prospectus For Offering $200M Mixed Shelf","publishedAt":1776456492},{"id":"n_51898413","summary":"https://www.sec.gov/Archives/edgar/data/1866030/000149315226017831/formf-3.htm","tickers":["AZ"],"headline":"A2Z Cust2Mate Files Prospectus For Offering $200M Mixed Shelf","publishedAt":1776456492},{"id":"n_51898390","summary":"Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will present new preclinical data highlighting that a mouse","tickers":["PYXS"],"headline":"Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNSCC Model With maMICVO In Combination With Anti-PD-1 at AACR 2026","publishedAt":1776456476},{"id":"n_51898390","summary":"Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will present new preclinical data highlighting that a mouse","tickers":["PYXS"],"headline":"Pyxis Oncology To Reveal New Preclinical Data Demonstrating Synergistic Anti-Tumor Activity In A HNSCC Model With maMICVO In Combination With Anti-PD-1 at AACR 2026","publishedAt":1776456476},{"id":"n_51898361","summary":"ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster","tickers":["ORIC"],"headline":"ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeting On Potential Of Rinzimetostat For Prostate Cancer Treatment","publishedAt":1776456424},{"id":"n_51898335","summary":"Hingham Institution (NASDAQ:HIFS) reported quarterly earnings of $4.79 per share. This is a 72.3 percent increase over earnings of $2.78 per share from the same period last year.  The company reported $12.515 million in","tickers":["HIFS"],"headline":"Hingham Institution Q1 Adj. EPS $4.79 Up From $2.78 YoY, Sales $12.515M Down From $17.585M YoY","publishedAt":1776456406},{"id":"n_51898218","summary":"","tickers":["OLMA"],"headline":"Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study","publishedAt":1776456260},{"id":"n_51898218","summary":"","tickers":["OLMA"],"headline":"Olema Pharmaceuticals Reveals Preclinical Data For Palazestrant and OP-3136 At The 2026 AACR Annual Meeting; Palazestrant's Mechanism Of Action Confirmed; Full Recruitment Of Corepressor Protein NCoR1 Enables Complete Antagonism Of The Estrogen Receptor; Palazestrant Is Currently Being Evaluated In Two Phase 3 Clinical Trials; OP-3136 Is Enrolling Patients In The Ongoing Phase 1 Study","publishedAt":1776456260},{"id":"n_51898216","summary":"Value Line, Inc. (NASDAQ – VALU) announced today that its Board of Directors has just raised its quarterly dividend, which will be $0.35 per common share ($1.40 annualized). The new higher cash dividend is payable on May","tickers":["VALU"],"headline":"Value Line Increases Quarterly Dividend From $0.33 To $0.35 Per Share","publishedAt":1776456260},{"id":"n_51898216","summary":"Value Line, Inc. (NASDAQ – VALU) announced today that its Board of Directors has just raised its quarterly dividend, which will be $0.35 per common share ($1.40 annualized). The new higher cash dividend is payable on May","tickers":["VALU"],"headline":"Value Line Increases Quarterly Dividend From $0.33 To $0.35 Per Share","publishedAt":1776456260},{"id":"n_51898203","summary":"Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster at the American","tickers":["CRDF"],"headline":"Cardiff Oncology To Present Preclinical Data On PLK1 Inhibitor Onvansertib In Combination With HER2-Targeted ADC, T-DXd, At AACR Annual Meeting 2026","publishedAt":1776456251},{"id":"n_51898203","summary":"Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster at the American","tickers":["CRDF"],"headline":"Cardiff Oncology To Present Preclinical Data On PLK1 Inhibitor Onvansertib In Combination With HER2-Targeted ADC, T-DXd, At AACR Annual Meeting 2026","publishedAt":1776456251},{"id":"n_51898165","summary":"Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per","tickers":["ADAG"],"headline":"Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026","publishedAt":1776456216},{"id":"n_51898164","summary":"Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics","tickers":["ACRV"],"headline":"Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026","publishedAt":1776456214},{"id":"n_51898164","summary":"Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics","tickers":["ACRV"],"headline":"Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026","publishedAt":1776456214},{"id":"n_51898125","summary":"XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio's clinically-validated masking technology, XTX601 was well","tickers":["XLO"],"headline":"Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026","publishedAt":1776456159}]},"exampleRequest":{"ticker":"BTC"},"tags":["x402"],"displayCostAmount":"0.002","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"unknown","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"down","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.002/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.002","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.002","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_jBgms2yQ_2w3RgXyytgiW","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.002","costPer":"request","priority":0,"asset":null,"unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Fetches the latest market news headlines with summaries and ticker tags for a specified stock or crypto ticker symbol","exampleAgentPrompt":"Pull the latest market news headlines for BTC from JeetScreener so I can see what stories are driving the move today.","exampleUseCases":null,"resultDescription":"An array of news items, each containing a unique article ID, a short summary, a headline, an array of associated ticker symbols, and a Unix timestamp of when the article was published. Articles are curated and tagged for active traders.","failureModes":["Missing or empty ticker parameter returns a validation error","Unknown or unsupported ticker symbol may return an empty array","Network or upstream news feed outage returns a 5xx error","Payment failure (402) if USDC balance is insufficient for the $0.002 per-call fee"],"whenToPreferThis":"Use this endpoint when you need current market news headlines filtered by a specific ticker symbol for trading context. Prefer this over generic web search when you want structured, trader-curated news with explicit ticker tagging and timestamps, especially for equities or crypto tickers. Best for real-time or near-real-time trading workflows.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T12:41:54.689Z","isFirstParty":false}